Tuesday, August 26, 2014 8:40:04 AM
http://www.clinuvel.com/en/pharmaceutical-development/orphan-drug-designation-odd-information
Regulatory agencies and governments offer incentives to drug developers to encourage the development of orphan drugs. Following a successful ODD, regulators commonly grant a period of market exclusivity to a drug, waive certain fees associated with the development and approval of a drug, and provide scientific assistance or access to specific grants programs.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
